Skip to Content


In the US, Brilinta (ticagrelor systemic) is a member of the drug class platelet aggregation inhibitors and is used to treat Acute Coronary Syndrome, Heart Attack, Myocardial Infarction - Prophylaxis and Prevention of Atherothrombotic Events.

US matches:

Ingredient matches for Brilinta


Ticagrelor is reported as an ingredient of Brilinta in the following countries:

  • Australia
  • Canada
  • China
  • Colombia
  • Georgia
  • Indonesia
  • Israel
  • Lebanon
  • Malaysia
  • Mexico
  • New Zealand
  • Philippines
  • Singapore
  • South Korea
  • Thailand
  • Turkey
  • United States

Important Notice: The international database is in BETA release. This means it is still under development and may contain inaccuracies. It is not intended as a substitute for the expertise and judgement of your physician, pharmacist or other healthcare professional. It should not be construed to indicate that the use of any medication in any country is safe, appropriate or effective for you. Consult with your healthcare professional before taking any medication.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.